Wave Life Sciences insider files to sell 21,000 shares via Morgan Stanley

Rhea-AI Filing Summary

Wave Life Sciences (WVE) Form 144 notices a proposed sale of 21,000 common shares by a person who exercised stock options on 08/15/2025 and intends to sell through Morgan Stanley Smith Barney LLC on NASDAQ at an aggregate market value of $194,250.00. The filing reports 159,140,460 shares outstanding. The same account sold 1,127 shares on 08/05/2025 for gross proceeds of $9,861.25. The seller represents they are not aware of undisclosed material adverse information about the issuer.

Positive

• Disclosure compliance: Form 144 filed providing broker, amount, acquisition method, and sale details.
• Transaction clarity: Date of acquisition (08/15/2025), method (stock option exercise), and payment type (cash) are explicitly stated.

Negative

• Insider sale disclosed: Proposed sale of 21,000 shares is reported.
• Recent sale activity: Seller executed a prior sale of 1,127 shares on 08/05/2025 for $9,861.25.

Insights

Securities Analyst

TL;DR Insider exercised options and filed to sell 21,000 shares, disclosed via Form 144; size is explicit but small relative to total shares outstanding.

The filing shows a proposed sale following a stock option exercise on the same date, with proceeds indicated as cash. The broker identified is Morgan Stanley Smith Barney LLC and the planned sale is on NASDAQ. A prior small sale of 1,127 shares for $9,861.25 is reported within the last three months. Based solely on the filing, this is a routine disclosure of an intended sale and complies with Rule 144 notice requirements; no additional financial metrics or company operational details are provided in this filing.

Corporate Governance Expert

TL;DR The filer fulfills disclosure obligations under Rule 144 by notifying a proposed sale after option exercise; no material undisclosed information is claimed.

The document includes the standard attestations that the seller does not possess undisclosed material adverse information and references reliance on Rule 10b5-1 language if applicable. The filing lists transaction dates, amounts, and broker details, enabling public transparency of insider selling activity. The filing does not contain governance changes, litigation, or other corporate actions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	21000	194250.00	159140460	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2025	Stock Option Exercise	ISSUER			21000	08/15/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
AIK NA TAN 7 Straits View #12-00 Marina One East Tower Singapore U0 018936	COMMON	08/05/2025	1127	9861.25

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Wave Life Sciences (WVE) Form 144 disclose?

The filing discloses a proposed sale of 21,000 common shares acquired by stock option exercise on 08/15/2025, to be sold via Morgan Stanley Smith Barney LLC on NASDAQ for an aggregate market value of $194,250.00.

Who is the broker handling the proposed WVE share sale?

The broker named in the Form 144 is Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY.

Did the filer sell any WVE shares recently?

Yes. The filing reports a sale of 1,127 shares on 08/05/2025 with gross proceeds of $9,861.25.

How many WVE shares are outstanding according to the filing?

The Form 144 lists 159,140,460 shares outstanding.

How was the 21,000-share position acquired?

The shares were acquired by stock option exercise on 08/15/2025, and payment was made in cash.